联合应用尤瑞克林及丁苯酞注射液治疗进展性脑梗死患者及对Hs-CRP影响的临床观察  

The Efficacy and the Changes of Serum High Sensitivity C Reactive Protein （ Hs-CRP） of Urinary Kallidinogenase Combined with Butylphthalide in the Treatment of Progressive Cerebral Infarction

作　　者：李卫征[1] 张慧敏[1] 

机构地区：[1]河南省新乡市中心医院神经内科,河南新乡453000

出　　处：《中国伤残医学》2015年第15期8-10,共3页Chinese Journal of Trauma and Disability Medicine

摘　　要：目的：观察联合应用尤瑞克林及丁苯酞注射液治疗进展性脑梗死患者的疗效及对超敏C反应蛋白（ Hs-CRP）的影响. 方法：将进展性脑梗死患者62例随机分成丁苯酞治疗组和对照组各31例. 用药后观察临床疗效及NIHSS评分,同时测定Hs-CRP水平变化. 结果：治疗组有效率（90.3%）高于对照组（70.9%）,治疗组治疗7天、14天后NIHSS评分较治疗前均明显降低（p〈0.01）,且治疗后14天治疗组较对照组NIHSS评分明显下降（p〈0.01）,差异均有统计学意义,同时能有效降低进展性脑梗死患者血清Hs-CPR水平. 结论：联合应用尤瑞克林及丁苯酞注射液对进展性脑梗死患者有较好的临床疗效.Objective：To study the efficacy and the changes of serum high sensitivity C reactive protein （ Hs-CRP） of urinary kal-lidinogenase combined with butylphthalide in the treatment of progressive cerebral infarction.Methods：62 patients with progressive cere-bral infarction..were randomly divided into treatment group and control group.After treatment, the clinical efficacy and the NIHSS score were observed, the level of Hs-CRP was measured.Results：the effective rate in the treatment group was higher than that in the control group（90.3%VS70.9%）（p〈0.05）,the NIHSS score at 7and 14days in the treatmen group were lower than that before treatment（p〈0.01）,the NIHSS score at 14days in the treatment group was lower than that in the control group （p〈0.01）.Urinary kallidinogenase com-bined with butylphthalide could decreased the level of serum hs-CRP in progressive cerebral infarction.Conclusion：Urinary kallidino-genase combined with butylphthalide were efficacy in the treatment of progressive cerebral infarction.

关 键 词：进展性脑梗死 尤瑞克林 丁苯酞 超敏C反应蛋白 

分 类 号：R743[医药卫生—神经病学与精神病学]